Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methimazole in Polymyositis and Dermatomyositis
NCT00001421Phase 2Completed
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Jun 1995
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methimazole in polymyositis (PM) and dermatomyositis (DM), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Primary endpoints: Tissue expression of HLA Class I at 6 months, Serum muscle enzyme levels at 6 months and 1 more. Started Jun 1995; status: completed.
02
Drugs
methimazole
03
Conditions
polymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on NCT00001421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001421.